<p>隨着全球市場在利率預期和人工智能驅動的樂觀情緒中航行，亞洲經濟體憑藉其獨特的增長敍事吸引了關注。在這種環境下，擁有高內部持股的公司尤其引人注目，因為它們通常反映出與企業最親近的人士的強烈信心。</p>
<h3>亞洲高內部持股的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>銅冠黃金集團 (SEHK:340)</td>
<td>30.1%</td>
<td>29.5%</td>
</tr>
<tr>
<td>蘇州三門科技 (SZSE:300522)</td>
<td>33.2%</td>
<td>84.7%</td>
</tr>
<tr>
<td>思能電氣 (SZSE:300827)</td>
<td>36.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>視源科技 (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>諾瑞 (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>老鋪黃金 (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>金迴路電子 (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>安科生物集團國際 (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>四月生物 (KOSDAQ:A397030)</td>
<td>31.1%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們高內部持股快速成長亞洲公司的 618 只股票的完整列表。</p>
<p>讓我們深入探討一些篩選出的優質選擇。</p>
<h2>康方生物 (SEHK:9926)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 康方生物是一家生物製藥公司，專注於全球抗體藥物的研究、開發、生產和商業化，市值為 1206.7 億港元。</p>
<p><strong>運營：</strong> 該公司通過其生物製藥產品的研究、開發、生產和銷售活動產生了 25.1 億人民幣的收入。</p>
<p><strong>內部持股：</strong> 18.1%</p>
<p><strong>收入增長預測：</strong> 每年 34.4%。</p>
<p>康方生物的增長軌跡得益於其高內部持股和強大的研發管道，專注於創新癌症療法。公司預測年收入增長 34.4%，超過香港市場。最近的進展包括針對肝細胞癌的 cadonilimab 全球二期臨牀試驗和肺癌研究的良好數據。儘管 2025 年上半年出現淨虧損，康方生物對雙特異性抗體如 ivonescimab 的戰略關注使其在滿足全球未滿足的醫療需求方面處於良好位置。</p>
<ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解康方生物的動態。</li>
<li>根據我們的估值報告，康方生物的股價可能偏高。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SEHK:9926 持股結構</p>
<h2>深圳拓邦 (SZSE:002139)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 深圳拓邦股份有限公司從事智能控制系統解決方案的研究、開發、生產和銷售，市值為 199.8 億人民幣。</p>
<p><strong>運營：</strong> 該公司在智能控制電子行業產生了 109.9 億人民幣的收入。</p>
<p><strong>內部持股：</strong> 23.8%</p>
<p><strong>收入增長預測：</strong> 每年 15.6%。</p>
<p>深圳拓邦的增長特點是戰略性全球擴張和高內部持股。公司預測年收入增長 15.6%，略高於中國市場平均水平。儘管 2025 年上半年淨收入有所下降，但其收益預計將顯著增長，年增長率為 27%。墨西哥工廠通過先進的生產線和認證提升了其全球製造效率，支持其智能控制器在多種應用中的表現，同時保持 32.6 倍的市盈率的競爭價值。</p>
<ul>
<li>點擊探索我們在深圳拓邦收益增長報告中的詳細發現。</li>
<li>我們的綜合估值報告提出，深圳拓邦的定價可能低於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown"/></p>
<p>截至 2025 年 9 月的 SZSE:002139 持股結構</p>
<h2>樂普醫療 (北京) (SZSE:300003)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 樂普醫療（北京）股份有限公司在醫療設備和製藥領域運營，市值為 349 億人民幣。</p>
<p><strong>運營：</strong> 樂普醫療（北京）股份有限公司通過其在醫療設備和製藥領域的運營產生收入。</p>
<p><strong>內部持股：</strong> 13.1%</p>
<p><strong>收入增長預測：</strong> 每年 14.1%。</p>
<p>樂普醫療（北京）展現出增長潛力，預計收益年增長率為 40%，超過中國市場。儘管最近利潤率下降至 4% 且股價波動較大，但其收入預計將以 14.1% 的速度增長，略高於市場平均水平。公司最近批准了對其章程的修訂，併為 2025 年每 10 股派發 1.63 元的中期現金紅利，反映出積極的股東參與。</p>
<ul>
<li>解鎖我們對樂普醫療（北京）股票分析的全面見解，詳見此增長報告。</li>
<li>我們編制的估值報告表明，樂普醫療（北京）的當前價格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 9 月的 SZSE:300003 收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>在這裏探索我們高內部持股快速成長亞洲公司的 618 個名字。</li>
<li>對其他可能性感興趣？發現下一個大機會，尋找財務穩健的平價股票，以平衡風險和回報。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

樂普醫療

康方生物

拓邦股份

<p>三家擁有顯著內部持股的亞洲成長公司因其預期的收入增長而受到關注：康方生物（SEHK:9926）預計年增長率為 34.4%，得益於其創新的癌症療法；深圳拓邦股份（SZSE:002139）預計增長 15.6%，受到全球擴張的支持；樂普醫療科技（SZSE:300003）預計增長 14.1%，儘管近期利潤率有所下降。這些公司反映了內部人士的強烈信心，並有望在各自的市場中表現優於大盤，儘管有些公司的估值可能高於基於財務數據的合理水平</p>

<p>As global markets navigate the complexities of interest rate expectations and AI-driven optimism, Asian economies are capturing attention with their unique growth narratives. In this environment, companies with high insider ownership can be particularly intriguing as they often reflect strong confidence from those closest to the business.</p>
<div class="lb-trans"><p>隨着全球市場在利率預期和人工智能驅動的樂觀情緒中航行，亞洲經濟體憑藉其獨特的增長敍事吸引了關注。在這種環境下，擁有高內部持股的公司尤其引人注目，因為它們通常反映出與企業最親近的人士的強烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亞洲高內部持股的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Tongguan Gold Group (SEHK:340)</td>
<td>30.1%</td>
<td>29.5%</td>
</tr>
<tr>
<td>Suzhou Sunmun Technology (SZSE:300522)</td>
<td>33.2%</td>
<td>84.7%</td>
</tr>
<tr>
<td>Sineng ElectricLtd (SZSE:300827)</td>
<td>36.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31.1%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>銅冠黃金集團 (SEHK:340)</td>
<td>30.1%</td>
<td>29.5%</td>
</tr>
<tr>
<td>蘇州三門科技 (SZSE:300522)</td>
<td>33.2%</td>
<td>84.7%</td>
</tr>
<tr>
<td>思能電氣 (SZSE:300827)</td>
<td>36.2%</td>
<td>27.6%</td>
</tr>
<tr>
<td>視源科技 (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>諾瑞 (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>老鋪黃金 (SEHK:6181)</td>
<td>35.5%</td>
<td>33.9%</td>
</tr>
<tr>
<td>金迴路電子 (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>富林精密 (SZSE:300432)</td>
<td>11.8%</td>
<td>50.7%</td>
</tr>
<tr>
<td>安科生物集團國際 (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>四月生物 (KOSDAQ:A397030)</td>
<td>31.1%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 618 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們高內部持股快速成長亞洲公司的 618 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>讓我們深入探討一些篩選出的優質選擇。</p>
</div><h2>Akeso (SEHK:9926)</h2>
<div class="lb-trans"><h2>康方生物 (SEHK:9926)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Akeso, Inc. is a biopharmaceutical company involved in the research, development, manufacture, and commercialization of antibody drugs globally, with a market cap of HK$120.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 康方生物是一家生物製藥公司，專注於全球抗體藥物的研究、開發、生產和商業化，市值為 1206.7 億港元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥2.51 billion from its activities in the research, development, production, and sale of biopharmaceutical products.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司通過其生物製藥產品的研究、開發、生產和銷售活動產生了 25.1 億人民幣的收入。</p>
</div><p><strong>Insider Ownership:</strong> 18.1%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 18.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 34.4% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 34.4%。</p>
</div><p>Akeso's growth trajectory is underscored by its high insider ownership and robust R&amp;D pipeline, focusing on innovative cancer therapies. The company forecasts revenue growth of 34.4% annually, outpacing the Hong Kong market. Recent advancements include the global Phase II trial of cadonilimab for hepatocellular carcinoma and promising data from lung cancer studies. Despite a net loss in H1 2025, Akeso's strategic focus on bispecific antibodies like ivonescimab positions it well in addressing unmet medical needs globally.</p>
<div class="lb-trans"><p>康方生物的增長軌跡得益於其高內部持股和強大的研發管道，專注於創新癌症療法。公司預測年收入增長 34.4%，超過香港市場。最近的進展包括針對肝細胞癌的 cadonilimab 全球二期臨牀試驗和肺癌研究的良好數據。儘管 2025 年上半年出現淨虧損，康方生物對雙特異性抗體如 ivonescimab 的戰略關注使其在滿足全球未滿足的醫療需求方面處於良好位置。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Akeso.</li>
<li>According our valuation report, there's an indication that Akeso's share price might be on the expensive side.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解康方生物的動態。</li>
<li>根據我們的估值報告，康方生物的股價可能偏高。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/7bb68bac-4b9b-4d33-b530-4a0b2460c566/chart/ownership-breakdown"/></p>
<p>SEHK:9926 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SEHK:9926 持股結構</p>
</div><h2>Shenzhen Topband (SZSE:002139)</h2>
<div class="lb-trans"><h2>深圳拓邦 (SZSE:002139)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shenzhen Topband Co., Ltd. is involved in the research, development, production, and sale of intelligent control system solutions both in China and internationally, with a market cap of CN¥19.98 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 深圳拓邦股份有限公司從事智能控制系統解決方案的研究、開發、生產和銷售，市值為 199.8 億人民幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥10.99 billion from its Intelligent Control Electronics Industry segment.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司在智能控制電子行業產生了 109.9 億人民幣的收入。</p>
</div><p><strong>Insider Ownership:</strong> 23.8%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 23.8%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 15.6% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 15.6%。</p>
</div><p>Shenzhen Topband's growth is marked by strategic global expansion and high insider ownership. The company forecasts revenue growth of 15.6% annually, slightly above the Chinese market average. Its earnings are expected to grow significantly at 27% per year, despite a recent dip in net income for H1 2025. The Mexico facility enhances its global manufacturing efficiency with advanced production lines and certifications, supporting its smart controller segment across diverse applications while maintaining competitive value with a P/E ratio of 32.6x.</p>
<div class="lb-trans"><p>深圳拓邦的增長特點是戰略性全球擴張和高內部持股。公司預測年收入增長 15.6%，略高於中國市場平均水平。儘管 2025 年上半年淨收入有所下降，但其收益預計將顯著增長，年增長率為 27%。墨西哥工廠通過先進的生產線和認證提升了其全球製造效率，支持其智能控制器在多種應用中的表現，同時保持 32.6 倍的市盈率的競爭價值。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Shenzhen Topband's earnings growth report.</li>
<li>Our comprehensive valuation report raises the possibility that Shenzhen Topband is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在深圳拓邦收益增長報告中的詳細發現。</li>
<li>我們的綜合估值報告提出，深圳拓邦的定價可能低於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/74319b67-902e-4891-925a-e5c8f8dc63c1/chart/ownership-breakdown"/></p>
<p>SZSE:002139 Ownership Breakdown as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SZSE:002139 持股結構</p>
</div><h2>Lepu Medical Technology (Beijing) (SZSE:300003)</h2>
<div class="lb-trans"><h2>樂普醫療 (北京) (SZSE:300003)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Lepu Medical Technology (Beijing) Co., Ltd. operates in the medical device and pharmaceutical sectors, with a market cap of CN¥34.90 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 樂普醫療（北京）股份有限公司在醫療設備和製藥領域運營，市值為 349 億人民幣。</p>
</div><p><strong>Operations:</strong> Lepu Medical Technology (Beijing) Co., Ltd. generates revenue from its operations in the medical device and pharmaceutical sectors.</p>
<div class="lb-trans"><p><strong>運營：</strong> 樂普醫療（北京）股份有限公司通過其在醫療設備和製藥領域的運營產生收入。</p>
</div><p><strong>Insider Ownership:</strong> 13.1%</p>
<div class="lb-trans"><p><strong>內部持股：</strong> 13.1%</p>
</div><p><strong>Revenue Growth Forecast:</strong> 14.1% p.a.</p>
<div class="lb-trans"><p><strong>收入增長預測：</strong> 每年 14.1%。</p>
</div><p>Lepu Medical Technology (Beijing) demonstrates growth potential with forecasted earnings growth of 40% annually, outpacing the Chinese market. Despite a recent decline in profit margins to 4% and high share price volatility, its revenue is expected to grow at 14.1%, slightly above the market average. The company recently approved amendments to its articles of association and an interim cash dividend of CNY 1.63 per 10 shares for 2025, reflecting active shareholder engagement.</p>
<div class="lb-trans"><p>樂普醫療（北京）展現出增長潛力，預計收益年增長率為 40%，超過中國市場。儘管最近利潤率下降至 4% 且股價波動較大，但其收入預計將以 14.1% 的速度增長，略高於市場平均水平。公司最近批准了對其章程的修訂，併為 2025 年每 10 股派發 1.63 元的中期現金紅利，反映出積極的股東參與。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Lepu Medical Technology (Beijing) stock in this growth report.</li>
<li>The valuation report we've compiled suggests that Lepu Medical Technology (Beijing)'s current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對樂普醫療（北京）股票分析的全面見解，詳見此增長報告。</li>
<li>我們編制的估值報告表明，樂普醫療（北京）的當前價格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/ce97139d-6fec-4731-8242-f12bbd463e94/chart/earnings-and-revenue-growth"/></p>
<p>SZSE:300003 Earnings and Revenue Growth as at Sep 2025</p>
<div class="lb-trans"><p>截至 2025 年 9 月的 SZSE:300003 收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Explore the 618 names from our Fast Growing Asian Companies With High Insider Ownership screener here.</li>
<li>Interested In Other Possibilities? Uncover the next big thing with financially sound penny stocks that balance risk and reward.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏探索我們高內部持股快速成長亞洲公司的 618 個名字。</li>
<li>對其他可能性感興趣？發現下一個大機會，尋找財務穩健的平價股票，以平衡風險和回報。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也不考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

3 家亞洲增長型公司，內部人士持股，預計收入增長可達 34%